BackgroundReceptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of muscles and neuronal precursors, angiogenesis and kidney formation. In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Promotes also differentiation and proliferation of hematopoietic cells. May regulate cortical bone osteogenesis (By similarity).
DescriptionMET Recombinant Monoclonal Antibody [2D12]. Unconjugated. Raised in: HEK293F Cell.
FormulationBuffer: Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
SpecificityHuman
IsotypeRabbit IgG
Uniprot IDP08581
PurificationAffinity Chromatography
ImmunogenA synthesized peptide derived from human Met (c-Met)
StorageUpon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Alternative NamesHepatocyte growth factor receptor (HGF receptor) (EC 2.7.10.1) (HGF/SF receptor) (Proto-oncogene c-Met) (Scatter factor receptor) (SF receptor) (Tyrosine-protein kinase Met), MET
ApplicationELISA, WB, IHC, IF, FC; Recommended dilution: WB:1:500-1:5000, IHC:1:50-1:200, IF:1:20-1:200, FC:1:20-1:200